Immune Cell SMN Loss Persists in Treated Spinal Muscular Atrophy
Spinal muscular atrophy is still usually framed as a motor neuron disease, but the newest work from the Journal of Clinical Investigation pushes the disorder firmly into immune territory as well. In this study, SMN expression varied sharply across immune cell types, and the same cellular imbalance appeared in both treated and untreated patients with spinal muscular atrophy. The pattern matters because it suggests that restoring SMN in the nervous system does not automatically normalize the immune system’s cellular architecture.
In neonatal mouse spleens, B cells carried the highest SMN expression, and that signal fell dramatically in SMA animals. The spleen is not a passive bystander in this setting; it is a major immune organ, and a reduction in SMN at that level hints at a broader defect in lymphoid development or survival. In the human adult peripheral blood mononuclear cell compartment, dendritic cells and monocytes showed the highest SMN levels. Patients with SMA, however, had fewer dendritic cells and more B cells than controls, a reversal that points to immune rebalancing rather than a single isolated cell loss.
A single protein deficit can echo through the immune system in more than one way.
Cell-Type Differences Reveal a Broader SMN Biology
The investigation focused on the fact that SMN is not uniformly expressed across immune cells, and that uneven distribution appears to shape the phenotype seen in SMA. Reduced SMN levels were linked with altered immune cell composition, not just in one model but across species and treatment settings. That cross-setting consistency strengthens the case that immune disruption is part of the disease biology itself rather than a side effect of a specific therapy.
Systemic therapy and CNS-restricted therapy produced similar differences in immune cell composition and SMN expression levels. An exploratory cohort of untreated patients did not show a substantial treatment-specific effect relative to controls either. Those findings make the immune signal harder to dismiss as drug-induced noise. They also suggest that current treatment strategies, while essential for neuromuscular outcomes, may leave peripheral immune abnormalities largely intact.
The mechanistic section of the study adds another layer. When THP-1 cells were driven toward differentiation with PMA, aberrant SMN splicing increased and SMN-positive Cajal bodies became more abundant. Cajal bodies are nuclear structures involved in RNA processing and ribonucleoprotein assembly, so their increase in the setting of aberrant splicing fits with a cellular response to disturbed RNA handling. In practical terms, immune differentiation itself seems to expose or amplify the molecular instability tied to SMN deficiency.
Persistent Immune Alterations May Outlast Motor Benefit
This work raises a clinically uncomfortable possibility: patients may receive meaningful neurologic benefit from SMN-modulating therapy while peripheral immune dysfunction continues underneath. The data do not show that treatment is irrelevant. They show something more specific and more consequential: immune cell composition and SMN expression remain abnormal despite therapy, whether the intervention reaches the entire body or is limited to the central nervous system.
That persistence offers a plausible explanation for why immune dysfunction could remain visible even in treated SMA. If the immune system develops under conditions of chronically reduced SMN, then later correction may arrive too late to fully reset lineage balance or cellular maturation. Developmental timing may matter more than we usually assume in inherited neurologic disease, especially when the mutation affects a ubiquitously expressed protein with RNA-processing functions.
The human data also fit that model. Adults with SMA showed reduced dendritic-cell frequencies and increased B-cell frequencies, while controls displayed a different distribution. Because dendritic cells are central to antigen presentation and immune orchestration, a lower frequency could influence how the immune system responds to infection or vaccination. A higher B-cell fraction may reflect compensation, skewed maturation, or altered cell survival. The study does not assign a single explanation, but it does show that the immune compartment is not normal.
What the Mouse and Human Data Say About Disease Mechanism
The mouse spleen findings were especially direct. At postnatal day 3, SMA mice had a significant loss of B cells in the spleen, and the flow cytometric analysis mapped that deficit across immune subsets with spectral precision. Because this occurred so early in life, the result supports a developmental component rather than a late inflammatory phenomenon. The immune system appears to be shaped by SMN deficiency from the start.
Human peripheral blood data echoed the same theme from a different angle. Dendritic cells and monocytes, the cells with the highest SMN expression in healthy adults, were precisely the populations that showed altered representation in SMA. The overlap between high-SMN cell types and altered cell frequencies is biologically suggestive. Cells that rely heavily on intact SMN biology may be especially vulnerable when the protein is lacking.
The study also avoided overclaiming therapeutic causality. Treated and untreated groups both carried immune alterations, and no substantial treatment-specific effect separated them from controls in the exploratory analysis. That finding narrows the interpretation to disease biology rather than treatment artifact. It also leaves open a difficult clinical question: whether peripheral immune correction would require a different drug, earlier exposure, or a strategy that specifically targets immune cells.
Why Peripheral Immunology Now Belongs in SMA Research
SMA research has rightly centered on motor function, survival, and respiratory outcomes. This study argues that immune profiling deserves a permanent place in that conversation. SMN expression is cell-specific, immune composition is altered, and those changes persist across treatment categories. The biology is not limited to the spinal cord or the neuromuscular junction.
For clinicians, the implication is straightforward even if the treatment path is not. Patients with SMA may carry an immunologic phenotype that is only partly captured by neurologic measures. For researchers, the next step is not a broad promise of better care but a tighter definition of which immune pathways remain abnormal, when those abnormalities begin, and whether they can be reversed without waiting for the nervous system to signal failure. The current data show persistence, not resolution, and they make the immune system impossible to ignore in the molecular story of SMA.